Specifically, Captivate Bio will distribute the firm's screenMatrix 96-well microplate system, as well as precoated consumables that promote chemically defined cell adhesion and expansion in serum-free, xeno-free induced pluripotent stem cell (iPSC) and mesenchymal stem cell (MSC) culture applications, according to Captivate Bio.

The DenovoMatrix consumables to be distributed by CaptivateBio will include the products myMatrixMSC and the newly released myMatrixiPSC.

Cytovia ramps up production of NK cells ahead of trials
Cytovia Therapeutics has signed two agreements for research and development and manufacturing operations to move the company's chimeric antigen receptor-natural...

Axol Bioscience to merge with Censo Biotechnologies
Provider of induced pluripotent stem cell-derived cells, media, and characterization services Axol Bioscience and contract research organization Censo...

Caribou nabs $115M to advance CRISPR-edited cell therapies
Caribou Biosciences has completed $115 million in financing to further develop its next-generation CRISPR technology platform and advance its pipeline...

Preclinical lung imaging offers effective evaluation of drug candidates
Drug discovery and development are arduous and costly endeavors, with nine in 10 drug candidates failing to gain approval. Preclinical imaging can help...

NoveCite touts preclinical results of COVID-19 allogenic stem cell therapy
Citius Pharmaceuticals subsidiary NoveCite has released data from a proof-of-concept large animal study of its proprietary induced mesenchymal stem cell...